55 related articles for article (PubMed ID: 12218419)
1. In vivo receptor assay with multiple ligand concentrations: an equilibrium approach.
Holden JE; Jivan S; Ruth TJ; Doudet DJ
J Cereb Blood Flow Metab; 2002 Sep; 22(9):1132-41. PubMed ID: 12218419
[TBL] [Abstract][Full Text] [Related]
2. Comparison of two compartmental models for describing receptor ligand kinetics and receptor availability in multiple injection PET studies.
Morris ED; Alpert NM; Fischman AJ
J Cereb Blood Flow Metab; 1996 Sep; 16(5):841-53. PubMed ID: 8784229
[TBL] [Abstract][Full Text] [Related]
3. Multiinjection approach for D2 receptor binding quantification in living rats using [11C]raclopride and the beta-microprobe: crossvalidation with in vitro binding data.
Mauger G; Saba W; Hantraye P; Dolle F; Coulon C; Bramoullé Y; Chalon S; Grégoire MC
J Cereb Blood Flow Metab; 2005 Nov; 25(11):1517-27. PubMed ID: 15917750
[TBL] [Abstract][Full Text] [Related]
4. Regulation of dopamine receptor and neuropeptide expression in the basal ganglia of monkeys treated with MPTP.
Betarbet R; Greenamyre JT
Exp Neurol; 2004 Oct; 189(2):393-403. PubMed ID: 15380489
[TBL] [Abstract][Full Text] [Related]
5. Ex vivo [11C]-(+)-PHNO binding is unchanged in animal models displaying increased high-affinity states of the D2 receptor in vitro.
McCormick PN; Kapur S; Reckless G; Wilson AA
Synapse; 2009 Nov; 63(11):998-1009. PubMed ID: 19598174
[TBL] [Abstract][Full Text] [Related]
6. In vivo vulnerability to competition by endogenous dopamine: comparison of the D2 receptor agonist radiotracer (-)-N-[11C]propyl-norapomorphine ([11C]NPA) with the D2 receptor antagonist radiotracer [11C]-raclopride.
Narendran R; Hwang DR; Slifstein M; Talbot PS; Erritzoe D; Huang Y; Cooper TB; Martinez D; Kegeles LS; Abi-Dargham A; Laruelle M
Synapse; 2004 Jun; 52(3):188-208. PubMed ID: 15065219
[TBL] [Abstract][Full Text] [Related]
7. Noninvasive nuclear imaging enables the in vivo quantification of striatal dopamine receptor expression and raclopride affinity in mice.
Fischer K; Sossi V; Schmid A; Thunemann M; Maier FC; Judenhofer MS; Mannheim JG; Reischl G; Pichler BJ
J Nucl Med; 2011 Jul; 52(7):1133-41. PubMed ID: 21680681
[TBL] [Abstract][Full Text] [Related]
8. Investigation of cooperativity in the binding of ligands to the D(2) dopamine receptor.
Vivo M; Lin H; Strange PG
Mol Pharmacol; 2006 Jan; 69(1):226-35. PubMed ID: 16204468
[TBL] [Abstract][Full Text] [Related]
9. Positron-labeled dopamine agonists for probing the high affinity states of dopamine subtype 2 receptors.
Hwang DR; Narendran R; Laruelle M
Bioconjug Chem; 2005; 16(1):27-31. PubMed ID: 15656572
[TBL] [Abstract][Full Text] [Related]
10. Dopamine D2 receptor radiotracers [(11)C](+)-PHNO and [(3)H]raclopride are indistinguishably inhibited by D2 agonists and antagonists ex vivo.
McCormick PN; Kapur S; Seeman P; Wilson AA
Nucl Med Biol; 2008 Jan; 35(1):11-7. PubMed ID: 18158938
[TBL] [Abstract][Full Text] [Related]
11. Effect of age on markers for monoaminergic neurons of normal and MPTP-lesioned rhesus monkeys: a multi-tracer PET study.
Doudet DJ; Rosa-Neto P; Munk OL; Ruth TJ; Jivan S; Cumming P
Neuroimage; 2006 Mar; 30(1):26-35. PubMed ID: 16378735
[TBL] [Abstract][Full Text] [Related]
12. Selective blockade of D(3) dopamine receptors enhances the anti-parkinsonian properties of ropinirole and levodopa in the MPTP-lesioned primate.
Silverdale MA; Nicholson SL; Ravenscroft P; Crossman AR; Millan MJ; Brotchie JM
Exp Neurol; 2004 Jul; 188(1):128-38. PubMed ID: 15191809
[TBL] [Abstract][Full Text] [Related]
13. Structural determinants of pharmacological specificity between D(1) and D(2) dopamine receptors.
Lan H; Durand CJ; Teeter MM; Neve KA
Mol Pharmacol; 2006 Jan; 69(1):185-94. PubMed ID: 16236817
[TBL] [Abstract][Full Text] [Related]
14. Amphetamine-sensitized animals show a marked increase in dopamine D2 high receptors occupied by endogenous dopamine, even in the absence of acute challenges.
Seeman P; Tallerico T; Ko F; Tenn C; Kapur S
Synapse; 2002 Dec; 46(4):235-9. PubMed ID: 12373738
[TBL] [Abstract][Full Text] [Related]
15. In vivo characterization of the pharmacokinetics and pharmacological properties of [11C]-(+)-PHNO in rats using an intracerebral beta-sensitive system.
Galineau L; Wilson AA; Garcia A; Houle S; Kapur S; Ginovart N
Synapse; 2006 Aug; 60(2):172-83. PubMed ID: 16715499
[TBL] [Abstract][Full Text] [Related]
16. Amphetamine pretreatment induces a change in both D2-Receptor density and apparent affinity: a [11C]raclopride positron emission tomography study in cats.
Ginovart N; Wilson AA; Houle S; Kapur S
Biol Psychiatry; 2004 Jun; 55(12):1188-94. PubMed ID: 15184038
[TBL] [Abstract][Full Text] [Related]
17. Dopamine displaces [3H]domperidone from high-affinity sites of the dopamine D2 receptor, but not [3H]raclopride or [3H]spiperone in isotonic medium: Implications for human positron emission tomography.
Seeman P; Tallerico T; Ko F
Synapse; 2003 Sep; 49(4):209-15. PubMed ID: 12827639
[TBL] [Abstract][Full Text] [Related]
18. Dopamine D2 receptor-mediated G protein activation assessed by agonist-stimulated [35S]guanosine 5'-O-(gamma-thiotriphosphate) binding in rat striatal membranes.
Odagaki Y; Toyoshima R
Prog Neuropsychopharmacol Biol Psychiatry; 2006 Sep; 30(7):1304-12. PubMed ID: 16824659
[TBL] [Abstract][Full Text] [Related]
19. Comparison of rat dopamine D2 receptor occupancy for a series of antipsychotic drugs measured using radiolabeled or nonlabeled raclopride tracer.
Barth VN; Chernet E; Martin LJ; Need AB; Rash KS; Morin M; Phebus LA
Life Sci; 2006 May; 78(26):3007-12. PubMed ID: 16434058
[TBL] [Abstract][Full Text] [Related]
20. Antagonist-radioligand binding to D2L-receptors in intact cells.
Packeu A; De Backer JP; Van Liefde I; Vanderheyden PM; Vauquelin G
Biochem Pharmacol; 2008 Jun; 75(11):2192-203. PubMed ID: 18436192
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
